论文部分内容阅读
目的研究分析重组人干扰素α-1b治疗流行性腮腺炎的临床应用效果。方法选取2014年7月至2015年8月收治的60例流行性腮腺炎患者,随机分成两组。30例为对照组,采用利巴韦林静脉注射方式治疗;30例为观察组,应用利巴韦林联合重组人干扰素α-1b肌肉注射方式治疗。统计比较两组患者腮腺消肿、退烧时间、治疗的总有效率以及并发生症的发生情况。结果观察组患者的腮腺消肿、退烧时间明显比对照组少,差异有统计学意义(P<0.05);观察组患者的治疗总有效率明显比对照组患者高,差异有统计学意义(P<0.05);观察组患者并发症的发生率显著比对照组患者低,差异有统计学意义(P<0.05)。结论重组人干扰素α-1 b治疗流行性腮腺炎可以显著提高治疗的有效率,降低并发症,疗效显著。
Objective To study the clinical effect of recombinant human interferon α-1b in the treatment of mumps. Methods Sixty patients with mumps admitted from July 2014 to August 2015 were randomly divided into two groups. Thirty patients were treated with ribavirin intravenously and 30 as observation group. Ribavirin was administered intramuscularly with recombinant interferon alpha-1b. Statistics were compared between the two groups parotid swelling, fever, the total effective rate of treatment and the occurrence of complications. Results The observation group had less parotid gland swelling and less fever than the control group (P <0.05). The total effective rate of the observation group was significantly higher than that of the control group (P <0.05). The incidence of complication in observation group was significantly lower than that in control group (P <0.05). Conclusion Recombinant human interferon α-1b treatment of mumps can significantly improve the efficiency of treatment, reduce complications, the effect is significant.